Oxford Ledge
Search
Agenus Inc. (NASDAQ: AGEN) is a $110M biotechnology company trading at $2.98 (−8.3% today). Figures from SEC EDGAR and market feeds; updated 2026-07-15 01:12 UTC.
Agenus is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious disease, with its primary focus on immuno-oncology using antibody-based treatments. The company's lead program consists of botensilimab and balstilimab, investigational drugs designed to activate anti-tumor immune responses and block immune evasion in cancer patients. Agenus has treated approximately 1,200 patients across multiple cancer types through clinical trials and government reimbursement programs, particularly in France, and is conducting a global Phase 3 trial in colorectal cancer.
Summarized from Agenus Inc.’s SEC filings · Read the filing ↗
| Quote | |
| Price | $2.98 |
| Change (1D) | -0.27 (-8.31%) |
| Market cap | $110M |
| Volume | 836.5K shares |
| 52-week range | $2.71 – $7.34 |
| Valuation | |
| EPS (TTM) | $0.00 |
| Return on equity | 0.04% |
| Returns | |
| 52-week return | +10.0% |
Agenus is a clinical-stage biotechnology company developing immunotherapies for cancer and infectious disease, with its primary focus on immuno-oncology using antibody-based treatments.
AGEN trades at $2.98, as of 2026-07-15.
Agenus Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-13. All filings link to their SEC EDGAR originals above.
SEC EDGAR filings and public market data feeds, fetched 2026-07-15 01:12 UTC. This page is also available as JSON at /api/data?ticker=AGEN and is emitted with FAQPage structured data for machine reading.
Charts, 10-year financials, peer comparison, screening and portfolio tracking for AGEN and 3,500+ tickers.
Create a free account — keep AGENGET /api/data?ticker=AGEN
This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt